Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kostos, Louise Kathleen
Lai, William Yu Ching
Lambroglou, Peter
Medhurst, Elizabeth
Buteau, James Patrick
Sandhu, Shahneen
Tran, Ben
Spain, Lavinia Anne
Conduit, Ciara
Wallace, Roslyn
Alipour, Ramin
Akhurst, Timothy J.
Kong, Grace
Cardin, Anthony
Saghebi, Javad
Kumar, Aravind Ravi
Hofman, Michael S.
Azad, Arun
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Mol Imaging & Therapeut Nucl Med, Canc Imaging, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Feldmann, Georg
    Brossart, Peter
    Fimmers, Rolf
    Essler, Markus
    Holdenrieder, Stefan
    Ahmadzadehfar, Hojjat
    PROSTATE, 2020, 80 (01): : 17 - 27
  • [22] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [23] [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
    Satapathy, Swayamjeet
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (08) : 2495 - 2503
  • [24] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-61 7 versus cabazitaxel
    Lorenz, Kunzell Judith
    AKTUELLE UROLOGIE, 2023, 54 (04) : 269 - 269
  • [25] Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer
    Santo, Giulia
    Santo, Gianpaolo Di
    Sviridenko, Anna
    Bayerschmidt, Steffen
    Wirth, Lukas
    Scherbauer, Fabian
    Lehmann, Peter
    von Guggenberg, Elisabeth
    Decristoforo, Clemens
    Heidegger-Pircher, Isabel
    Bektic, Jasmin
    Virgolini, Irene
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 52 (01) : 354 - 365
  • [26] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [27] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [28] Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617
    Muniz, Miguel
    Sartor, Oliver
    Orme, Jacob J.
    Koch, Regina M.
    Rosenow, Hana R.
    Mahmoud, Ahmed M.
    Andrews, Jack R.
    Kase, Adam M.
    Riaz, Irbaz B.
    Bilgin, Gokce Belge
    Thorpe, Matthew P.
    Kendi, A. Tuba
    Johnson, Geoffrey B.
    Ravi, Praful
    Kwon, Eugene D.
    Childs, Daniel S.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1932 - 1938
  • [29] RECIP 1.0 Predicts Progression-Free Survival After [ 177 Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Gafita, Andrei
    Djaileb, Loic
    Rauscher, Isabel
    Fendler, Wolfgang P.
    Hadaschik, Boris
    Rowe, Steven P.
    Herrmann, Ken
    Solnes, Lilja B.
    Calais, Jeremie
    Rettig, Matthew B.
    Weber, Manuel
    Farolfi, Andrea
    Benz, Matthias R.
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (06) : 917 - 922
  • [30] Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
    Tagawa, Scott T.
    Armstrong, Andrew J.
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    De Bono, Johann S.
    Adra, Nabil
    Desilvio, Michelle
    Messmann, Richard
    Holder, Geoffrey
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345